While all of these cytokines have been shown to be critical sources of Signal 3, agents that block TNF, IL-6, and IL-1, as well as the T cell-derived growth factor IL-2 have been studied as potential modes of treatment in acute GVHD. Here, TNF is linked to acute graft versus host disease.